Regular and extended-release formulations of zolpidem [Ambien and Ambien CR; sanofi-aventis] have been granted paediatric exclusivity by the US FDA.

Source: Inpharma, Volume 1, Number 1567, 2006-12-09 , pp. 22-22(1)

Publisher: Adis International

Keywords: Children; Controlled-release-drugs; Development-status; Insomnia, treatment; Product-approvals; Zolpidem, therapeutic use

Document Type: Short communication

Publication date: 2006-01-01

• In this: publication
• By this: publisher
• In this Subject: Pharmacology

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers